JP2023537534A5 - - Google Patents

Info

Publication number
JP2023537534A5
JP2023537534A5 JP2023510439A JP2023510439A JP2023537534A5 JP 2023537534 A5 JP2023537534 A5 JP 2023537534A5 JP 2023510439 A JP2023510439 A JP 2023510439A JP 2023510439 A JP2023510439 A JP 2023510439A JP 2023537534 A5 JP2023537534 A5 JP 2023537534A5
Authority
JP
Japan
Prior art keywords
epitope
fragment
antibody
polyspecific
polyspecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023510439A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537534A (ja
JP7847579B2 (ja
Filing date
Publication date
Priority claimed from PCT/GB2020/051959 external-priority patent/WO2021032963A1/en
Priority claimed from GBGB2102224.9A external-priority patent/GB202102224D0/en
Priority claimed from GBGB2102222.3A external-priority patent/GB202102222D0/en
Application filed filed Critical
Priority claimed from PCT/IB2021/057509 external-priority patent/WO2022034562A1/en
Publication of JP2023537534A publication Critical patent/JP2023537534A/ja
Publication of JP2023537534A5 publication Critical patent/JP2023537534A5/ja
Application granted granted Critical
Publication of JP7847579B2 publication Critical patent/JP7847579B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023510439A 2020-08-14 2021-08-14 多特異性抗tcrデルタ可変1抗体 Active JP7847579B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBPCT/GB2020/051959 2020-08-14
PCT/GB2020/051959 WO2021032963A1 (en) 2019-08-16 2020-08-14 Therapeutic uses of anti-tcr delta variable 1 antibodies
GBGB2102224.9A GB202102224D0 (en) 2021-02-17 2021-02-17 Anti-TRC delta variable 1 antibodies
GB2102222.3 2021-02-17
GB2102224.9 2021-02-17
GBGB2102222.3A GB202102222D0 (en) 2021-02-17 2021-02-17 Multispecific anti-TCR delta variable 1 antibodies
PCT/IB2021/057509 WO2022034562A1 (en) 2020-08-14 2021-08-14 Multispecific anti-tcr delta variable 1 antibodies

Publications (3)

Publication Number Publication Date
JP2023537534A JP2023537534A (ja) 2023-09-01
JP2023537534A5 true JP2023537534A5 (cg-RX-API-DMAC7.html) 2024-08-21
JP7847579B2 JP7847579B2 (ja) 2026-04-17

Family

ID=80247426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023510439A Active JP7847579B2 (ja) 2020-08-14 2021-08-14 多特異性抗tcrデルタ可変1抗体

Country Status (18)

Country Link
EP (7) EP4218932A3 (cg-RX-API-DMAC7.html)
JP (1) JP7847579B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230083267A (cg-RX-API-DMAC7.html)
CN (1) CN116209456A (cg-RX-API-DMAC7.html)
AU (1) AU2021323512A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023002741A2 (cg-RX-API-DMAC7.html)
CA (1) CA3188682A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023003009A2 (cg-RX-API-DMAC7.html)
DK (2) DK4269444T5 (cg-RX-API-DMAC7.html)
ES (2) ES2943063T5 (cg-RX-API-DMAC7.html)
FI (2) FI4010082T4 (cg-RX-API-DMAC7.html)
IL (1) IL300517A (cg-RX-API-DMAC7.html)
LT (2) LT4269444T (cg-RX-API-DMAC7.html)
MX (1) MX2023001728A (cg-RX-API-DMAC7.html)
PL (2) PL4269444T3 (cg-RX-API-DMAC7.html)
PT (2) PT4269444T (cg-RX-API-DMAC7.html)
SI (2) SI4010082T2 (cg-RX-API-DMAC7.html)
WO (1) WO2022034562A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2943063T5 (en) 2020-08-14 2026-05-05 Gammadelta Therapeutics Ltd Multispecific anti-tcr delta variable 1 antibodies
EP4544302A1 (en) * 2022-06-23 2025-04-30 LAVA Therapeutics N.V. Assay for t cell dependent multispecific compounds
EP4680729A1 (en) * 2023-03-17 2026-01-21 Legend Biotech Ireland Limited Methods of culturing v delta 1 t cells
WO2025147597A1 (en) * 2024-01-05 2025-07-10 Eugit Therapeutics, Inc. Targeting payloads
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2026026858A1 (en) * 2024-07-30 2026-02-05 Biomap (Suzhou) Intelligent Technology Limited Dsg2 antibody and uses thereof
WO2026087748A1 (en) 2024-10-24 2026-04-30 Avidicure Ip B.V. Multispecific antigen binding proteins for the expansion of γδ t cells and use thereof
WO2026087747A1 (en) 2024-10-24 2026-04-30 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of γδ1 t cells and use thereof
US20260152558A1 (en) * 2024-11-27 2026-06-04 Gammadelta Therapeutics Ltd Multispecific anti-tcr delta variable 1 antibodies
WO2026152120A2 (en) 2025-01-13 2026-07-16 HCW Biologics, Inc. Chimeric polypeptides and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
WO2015063069A1 (en) * 2013-10-28 2015-05-07 Benjamin Felder Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
JP6799895B2 (ja) 2015-06-09 2020-12-16 リンファクト−リンフォサイト アクティベイション テクノロジーズ エス.エー. TCRγδ+T細胞の生産方法
US10946095B2 (en) 2015-09-02 2021-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT)
CN108473958A (zh) 2015-10-30 2018-08-31 癌症研究技术有限公司 非造血组织驻留γδT细胞的扩增及这些细胞的用途
CN118421557A (zh) 2016-05-12 2024-08-02 阿迪塞特治疗公司 选择性扩增γδT细胞群的方法及其组合物
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
EP3490675A4 (en) 2016-07-29 2020-07-29 New York University T GAMMA DELTA LYMPHOCYTES USED AS A TARGET FOR THE TREATMENT OF SOLID TUMORS
US10546518B2 (en) 2017-05-15 2020-01-28 Google Llc Near-eye display with extended effective eyebox via eye tracking
WO2019005637A2 (en) 2017-06-25 2019-01-03 Systimmune, Inc. MULTIPECIFIC ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF
WO2019147735A1 (en) 2018-01-23 2019-08-01 New York University Antibodies specific to delta 1 chain of t cell receptor
JP7457007B2 (ja) * 2018-09-19 2024-03-27 ラヴァ・セラピューティクス・エヌ・ヴイ 二重作用CD1d免疫グロブリン
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
CA3127103A1 (en) * 2019-01-23 2020-07-30 New York University Antibodies specific to delta 1 chain of t cell receptor
WO2020159368A1 (en) * 2019-02-01 2020-08-06 Lava Therapeutics B.V. Novel cd40-binding antibodies
CA3136251A1 (en) 2019-04-08 2020-10-15 Memorial Sloan Kettering Cancer Center Cd19 antibodies and methods of using the same
CA3148588A1 (en) 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Ex vivo gamma delta t cell populations
JP2022545196A (ja) 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗tcrデルタ可変1抗体の治療的使用
ES2943063T5 (en) 2020-08-14 2026-05-05 Gammadelta Therapeutics Ltd Multispecific anti-tcr delta variable 1 antibodies
KR20230160253A (ko) 2021-02-17 2023-11-23 감마델타 테라퓨틱스 엘티디 항-tcr 델타 가변 1 항체

Similar Documents

Publication Publication Date Title
JP2024506682A5 (cg-RX-API-DMAC7.html)
JP2023126852A5 (cg-RX-API-DMAC7.html)
FI3535392T3 (fi) Immunologisesti havaittavia solupintavariantteja käytettäväksi soluterapiassa
JP2019533450A5 (cg-RX-API-DMAC7.html)
JP2023515199A5 (cg-RX-API-DMAC7.html)
JP2025513879A5 (cg-RX-API-DMAC7.html)
US20220403025A1 (en) Therapeutic uses of anti-tcr delta variable 1 antibodies
JP7017506B2 (ja) 系統特異的抗原の阻害のための組成物および方法
IL295897A (en) Materials and methods for modulating an immune response
JP2017506636A5 (cg-RX-API-DMAC7.html)
JP2004528806A5 (cg-RX-API-DMAC7.html)
US20060003452A1 (en) Vector packaging cell line
JP2025517657A5 (cg-RX-API-DMAC7.html)
IL300517A (en) Multispecific antibodies against variable chain delta 1 on TCR
US20240382521A1 (en) Methods of engineering immune cells having reduced fratricidal activity
JP2025516377A (ja) 多重特異性抗体を含む治療薬及び腫瘍治療におけるその使用
CA3236152A1 (en) Compositions and methods for erm2 modification
WO2023049926A2 (en) Fusion polypeptides for genetic editing and methods of use thereof
US20230414755A1 (en) Methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors
US20240344058A1 (en) Compositions and methods for bcma modification
US20260083847A1 (en) T-cell receptors and compositions thereof for targeting mutant ras
Clark et al. CD nomenclature 2015: human leukocyte
JP2025513894A5 (cg-RX-API-DMAC7.html)
CN116744963A (zh) 与表达嵌合抗原受体的经基因工程化的细胞有关的方法和组合物
Alaverdi Monoclonal antibodies to mouse cell‐surface antigens